Invivyd Inc (NAS:IVVD)
$ 0.51 -0.0204 (-3.85%) Market Cap: 61.00 Mil Enterprise Value: -44.23 Mil PE Ratio: 0 PB Ratio: 0.73 GF Score: 30/100

Invivyd Inc at H.C. Wainwright BioConnect Investor Conference Transcript

May 02, 2023 / 08:00PM GMT
Release Date Price: $1.15 (-7.26%)
Patrick Ralph Trucchio
H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst

Hello, everyone, and good afternoon, and welcome back to H.C. Wainwright BioConnect Investor Conference in partnership with NASDAQ. I'm Patrick Trucchio. I'm the senior health care analyst at H.C. Wainwright. It's my pleasure to introduce our next speaker, Dave Hering, CEO of Invivyd, a clinical-stage biopharmaceutical company focused on delivering antibody-based therapies to protect vulnerable people from devastating consequences of circulating viral threats, starting with SARS-CoV-2 and then expanding to flu and other high-need indications.

Questions & Answers

Patrick Ralph Trucchio
H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst

So maybe we can start first with just some brief background on Invivyd, including the history of the company.

David Hering
Invivyd, Inc. - CEO & Director

Sure. Thanks, Patrick, and thanks

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot